Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	20.95	41.92	45.2	100.44	178.87
Short-Term Investments	-	-	35.8	177.19	197.68
Cash & Short-Term Investments	20.95	41.92	81	277.63	376.55
Cash Growth	-50.03%	-48.25%	-70.82%	-26.27%	-41.30%
Accounts Receivable	0.37	0.53	0.92	3.68	6.01
Other Receivables	10.14	4.07	3.14	0.79	0.35
Receivables	10.51	4.6	4.07	4.47	6.36
Prepaid Expenses	4.37	5.18	9.26	18.22	15.86
Total Current Assets	35.83	51.69	94.33	300.33	398.77
Property, Plant & Equipment	14.11	34.76	52.87	125.53	124.7
Long-Term Investments	-	-	-	29.85	88.17
Goodwill	-	-	-	37.55	39.7
Other Intangible Assets	-	-	-	50.73	53.76
Long-Term Deferred Tax Assets	-	-	-	1.12	1.06
Other Long-Term Assets	9.81	15.19	18.13	17.41	15.76
Total Assets	59.75	101.64	165.32	562.51	721.92
Accounts Payable	14.44	15.49	15.26	22.42	9.76
Accrued Expenses	25.43	17.56	16.15	33.39	28.39
Current Portion of Leases	1.7	4.31	4.59	4.12	4.03
Current Unearned Revenue	0.9	7.56	-	51.78	85.71
Other Current Liabilities	-	0.9	11.73	-	-
Total Current Liabilities	42.47	45.81	47.73	111.71	127.89
Long-Term Leases	25.09	26.25	33.52	38.99	44.06
Long-Term Unearned Revenue	5.87	5.87	-	109.38	166.78
Long-Term Deferred Tax Liabilities	-	-	-	6.27	6.65
Other Long-Term Liabilities	0.58	0.93	1.19	1.21	1.22
Total Liabilities	74.01	78.87	82.43	267.55	346.58
Common Stock	3.51	2.13	1.78	1.67	1.46
Additional Paid-In Capital	1,611	1,532	1,492	1,450	1,334
Retained Earnings	-1,627	-1,504	-1,406	-1,149	-956.27
Comprehensive Income & Other	-1.46	-7.53	-4.6	-8.4	-3.99
Total Common Equity	-14.27	22.77	82.89	294.96	375.34
Shareholders' Equity	-14.27	22.77	82.89	294.96	375.34
Total Liabilities & Equity	59.75	101.64	165.32	562.51	721.92
Total Debt	26.8	30.57	38.1	43.11	48.08
Net Cash (Debt)	-5.85	11.35	42.9	264.37	416.64
Net Cash Growth	-	-73.54%	-83.77%	-36.55%	-35.89%
Net Cash Per Share	-0.02	0.06	0.25	1.71	2.88
Filing Date Shares Outstanding	414.27	224.71	178.91	168.48	145.97
Total Common Shares Outstanding	350.69	212.84	178.13	166.79	145.92
Working Capital	-6.64	5.89	46.6	188.62	270.88
Book Value Per Share	-0.04	0.11	0.47	1.77	2.57
Tangible Book Value	-14.27	22.77	82.89	206.68	281.88
Tangible Book Value Per Share	-0.04	0.11	0.47	1.24	1.93
Machinery	31.42	32.78	47.02	54.72	49.85
Construction In Progress	-	-	1.09	14.77	4.73
Leasehold Improvements	21.83	24.92	29.81	30.57	21.97

Source: S&P Global Market Intelligence. Standard template. Financial Sources.